0001104659-22-061591.txt : 20220516 0001104659-22-061591.hdr.sgml : 20220516 20220516205453 ACCESSION NUMBER: 0001104659-22-061591 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220512 FILED AS OF DATE: 20220516 DATE AS OF CHANGE: 20220516 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jovan-Embiricos Morana CENTRAL INDEX KEY: 0001575745 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39856 FILM NUMBER: 22931944 MAIL ADDRESS: STREET 1: C/O RADIUS HEALTH, INC. STREET 2: 201 BROADWAY, 6TH FLOOR CITY: BOSTON STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: F2 Vision SCS CENTRAL INDEX KEY: 0001838409 STATE OF INCORPORATION: N4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39856 FILM NUMBER: 22931945 BUSINESS ADDRESS: STREET 1: 74 GRAND RUE CITY: LUXEMBURG STATE: N4 ZIP: L-1660 BUSINESS PHONE: 352-277-250-5 MAIL ADDRESS: STREET 1: 74 GRAND RUE CITY: LUXEMBURG STATE: N4 ZIP: L-1660 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cullinan Oncology, Inc. CENTRAL INDEX KEY: 0001789972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813867811 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 520 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-410-4650 MAIL ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 520 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Management, Inc. DATE OF NAME CHANGE: 20210107 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Oncology, LLC DATE OF NAME CHANGE: 20191001 4 1 tm2215669-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-05-12 0 0001789972 Cullinan Oncology, Inc. CGEM 0001838409 F2 Vision SCS 74 GRAND-RUE LUXEMBOURG V8 L-1660 SWITZERLAND 0 0 1 0 0001575745 Jovan-Embiricos Morana C/O LJ MANAGEMENT (SUISSE) SA 8, RUE SAINT-LEGER GENEVA V8 CH-1205 SWITZERLAND 0 0 1 0 Common Stock 2022-05-12 4 S 0 264072 9.2497 D 1460539 D Common Stock 2022-05-13 4 S 0 85319 9.9631 D 1375220 D Common Stock 2022-05-13 4 S 0 34189 10.4810 D 1341031 D Common Stock 2022-05-16 4 S 0 35158 11.2301 D 1305873 D Common Stock 1136525 I By Globeways Holdings Ltd. Common Stock 639295 I By F2 Bioscience I 2017 Ltd. Common Stock 325333 I By F2 MG Ltd. Common Stock 622175 I By F2-TPO Investments, LLC Common Stock 71599 I By F2 Bio TD, LLC Common Stock 214798 I By F2 MC, LLC Common Stock 104762 I By F2 GC, LLC Common Stock 112507 I By Morana Jovan-Embiricos The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.58, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.40 to $10.395, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.40 to $10.65, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.74, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. These securities are owned directly by Globeways Holdings Limited ("Globeways"). Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. These securities are owned directly by F2 GC LLC ("F2 GC"). Globeways II is the appointed manager of F2 GC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. These securities are owned directly by Dr. Jovan-Embiricos. Each of the Reporting Persons except for Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 Vision SCS /s/ Alain Renard /s/ Christian Francois 2022-05-16 Morana Jovan-Embiricos /s/ Morana Jovan-Embiricos 2022-05-16